GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010563113 | Thyroid | PTC | negative regulation of phosphorus metabolic process | 219/5968 | 442/18723 | 4.47e-15 | 3.07e-13 | 219 |
GO:0045936113 | Thyroid | PTC | negative regulation of phosphate metabolic process | 218/5968 | 441/18723 | 7.08e-15 | 4.75e-13 | 218 |
GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
GO:005149526 | Thyroid | PTC | positive regulation of cytoskeleton organization | 121/5968 | 226/18723 | 1.04e-11 | 4.27e-10 | 121 |
GO:0031346110 | Thyroid | PTC | positive regulation of cell projection organization | 173/5968 | 353/18723 | 1.09e-11 | 4.40e-10 | 173 |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:001810518 | Thyroid | PTC | peptidyl-serine phosphorylation | 143/5968 | 315/18723 | 2.94e-07 | 5.04e-06 | 143 |
GO:001820916 | Thyroid | PTC | peptidyl-serine modification | 151/5968 | 338/18723 | 4.61e-07 | 7.51e-06 | 151 |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:005076716 | Thyroid | PTC | regulation of neurogenesis | 156/5968 | 364/18723 | 5.86e-06 | 7.05e-05 | 156 |
GO:190211516 | Thyroid | PTC | regulation of organelle assembly | 88/5968 | 186/18723 | 7.41e-06 | 8.65e-05 | 88 |
GO:007190210 | Thyroid | PTC | positive regulation of protein serine/threonine kinase activity | 93/5968 | 200/18723 | 1.01e-05 | 1.12e-04 | 93 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NTRK3 | SNV | Missense_Mutation | novel | c.1106N>A | p.Thr369Asn | p.T369N | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | novel | c.2258N>G | p.Val753Gly | p.V753G | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | | c.1718C>T | p.Ala573Val | p.A573V | Q16288 | protein_coding | tolerated(0.17) | benign(0.088) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | | c.917N>C | p.Arg306Pro | p.R306P | Q16288 | protein_coding | tolerated(0.23) | benign(0.346) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
NTRK3 | SNV | Missense_Mutation | rs374759890 | c.1744C>T | p.Arg582Trp | p.R582W | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
NTRK3 | SNV | Missense_Mutation | | c.2481N>T | p.Leu827Phe | p.L827F | Q16288 | protein_coding | deleterious(0) | benign(0.403) | TCGA-GM-A2DM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
NTRK3 | insertion | In_Frame_Ins | novel | c.1745_1746insTCACATGTGGCTAGTTTTTACCATACAGGGAAGCAC | p.Arg582_Lys583insHisMetTrpLeuValPheThrIleGlnGlySerThr | p.R582_K583insHMWLVFTIQGST | Q16288 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
NTRK3 | SNV | Missense_Mutation | rs866711936 | c.364N>A | p.Ala122Thr | p.A122T | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NTRK3 | SNV | Missense_Mutation | novel | c.1636G>A | p.Glu546Lys | p.E546K | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | | c.485N>C | p.Phe162Ser | p.F162S | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | inhibitor | 381744997 | REPOTRECTINIB | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | inhibitor | 252827368 | PEXIDARTINIB | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | MK-2461 | MK-2461 | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | Cyclopenta[d]pyrimidine derivative 1 | | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | SNS-314 | SNS-314 | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | SB-202190 | SB-202190 | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | GW441756X | GW441756X | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | IFN | | 15875206 |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | | REPOTRECTINIB | REPOTRECTINIB | 30093503 |